Introduction {#Sec1}
============

Acne is a skin disease affecting up to 80% of young adults and up to 5% of older adults. Many causes are involved in the pathogenesis of acne, including increased sebum production, follicular hyperkeratinization, colonization with *Propionibacterium acnes*, inflammatory response, and other unproven factors such as vitamin D deficiency \[[@CR1], [@CR2]\].

Acne scars occur as a consequence of inflammatory disorders in the dermis around the hair follicle. They are broadly classified into three types: atrophic, hypertrophic, and keloidal scars. Atrophic scars are the most common type, which can be further classified according to their depth, width, and three-dimensional architecture into rolling, icepick, and boxcar scars \[[@CR1], [@CR3]\].

Severe psychological depression and social withdrawal can result from acne scarring, which represent undesirable complications of acne vulgaris \[[@CR3]\]. Acne scars can be assessed using many scoring systems, such as the Qualitative Global Grading System presented by Goodman and Baron, which considers the form, type, intensity, and evolution period of the scar \[[@CR4], [@CR5]\].

Fractional nonablative resurfacing laser treatment relies on a unique mechanism of action that repairs a fraction of the skin at a time. Laser is used to resurface the epidermis and at the same time heat the dermis to promote formation of new collagen \[[@CR6]\]. Fractional erbium-YAG laser 2940 nm (Er-YAG) treatment targets both the epidermis and dermis, creating small zones of microdamage separated by zones of nondamaged tissue that favor a rapid healing process and treatment of acne scarring. It has minimal complications and side effects such as erythema and postinflammatory hyperpigmentation (PIH) \[[@CR5], [@CR7]\].

Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma. It contains growth factors, especially epidermal growth factor, platelet-derived growth factor, transforming growth factor beta (TGF-b), and vascular endothelial growth factor \[[@CR8]\]. These factors are known to regulate various processes including cell migration, attachment, proliferation, and differentiation and to promote extracellular matrix production by binding to specific cell surface receptors \[[@CR9]\]. It is used in many fields of dermatology nowadays to promote wound healing and accelerate new collagen formation. It can also be used as a treatment option in acne scarring \[[@CR10]--[@CR12]\]. PRP has minor side effects such as erythema and painful injection \[[@CR3], [@CR10], [@CR11]\].

Although there are many choices for treatment of acne scarring, to date there is no standard line of therapy. The aim of the current study is to compare the efficacy and safety of combined autologous PRP with Er-YAG laser for treatment of atrophic acne scars versus Er-YAG or PRP alone.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This randomized clinical trial (RCT) was performed at the Outpatient Clinic of Dermatology, Venerology and Andrology Department, South Valley University on 75 patients with atrophic postacne scars in the period from June 2017 to August 2018.

The sample size calculation was carried out using G\*Power-3 software \[[@CR13]\]. A minimum sample size of 75 acne scar patients (divided into three equal groups: 25 PRP, 25 Er-YAG laser, and 25 combined treatment) was calculated to detect an effect size of 0.3 in the percentage improvement, with an error probability of 0.05 and 90% power in a two-tailed test.

Patients with no active acne or only atrophic postacne scars as classified based on Goodman and Baron's qualitative classification were included in this trial. Moreover, patients with positive history of keloidal tendency, bleeding tendency, platelet disorder, any acute infection on the face (herpes or folliculitis), human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or autoimmune diseases, or on immunosuppressive drugs or topical or systemic acne treatments, or who had undergone interventions such as microdermabrasion and needling in the 3 months prior to the study were excluded from the trial.

Randomization {#Sec4}
-------------

Eligible participants were divided into three equal groups based on randomized coded cards. Randomization was carried out using tables of random numbers arranged in consecutive order. The allocation of patients and follow-up was performed by assistants.

Treatment Protocol {#Sec5}
------------------

Each group was treated according to the following regimens: Group A was subjected to 12 sessions of intradermal injection of PRP at 2-week intervals. Group B was subjected to six fractional nonablative Er-YAG laser (FotonaXs Dynamis, Slovenia) sessions at 4-week intervals. Group C was subjected to the combination of the two treatment modalities.

Laser Parameters {#Sec6}
----------------

Five passes in vertical, horizontal, and oblique directions were applied over the scar areas. Parameters for each setting were kept constant for all patients. The first pass was conducted on the entire face area with parameters of energy of 600 mJ in micro-short pulse mode (MSP) with spot size of 7 mm diameter and frequency of 5 Hz. The second pass was applied with the same parameters but to the scar area only. The third pass was applied on the entire face area with parameters of energy of 1000 mJ in short pulse mode (SP) with spot size of 7 mm diameter and frequency of 5 Hz. The fourth pass was applied on the scar area only with parameters of energy of 1200 mJ in short pulse mode (SP) with spot size of 7 mm diameter and frequency of 5 Hz. The fifth pass was applied to the scar area only with parameters of energy of 1500 mJ in extra-long pulse mode (XLP) with spot size of 7 mm diameter and frequency of 5 Hz.

PRP Preparation and Injection {#Sec7}
-----------------------------

Venous blood (10 mL) was obtained under sterile conditions and collected in sterile tubes containing sodium citrate 3.8%. Each tube was centrifuged at 2000 (rpm) for 7 min. The plasma and buffy coat were gently aspirated from each tube and transferred to another tube (plain tube without anticoagulant). Further centrifugation was carried out at 4000 rpm for 7--10 min, thus obtaining a two-part plasma: an uppermost part consisting of platelet-poor plasma (PPP), and a lower part consisting of PRP.

The mean blood platelet level was 200,000 ± 5000/μL. Although the platelet count of PRP has not been optimized, a platelet concentration of more than 1 million/μL (equal to four to seven times mean levels) is generally regarded as a suitable therapeutic concentration \[[@CR11]\]. PRP was injected in acne scars under aseptic precautions using a disposable 27-gauge needle. Treatments were given every 2 weeks for 6 months with a total of 12 sessions.

Outcomes Assessment {#Sec8}
-------------------

### Qualitative Scarring Grading System of Goodman and Baron {#Sec9}

Patients were evaluated using the pretreatment and posttreatment qualitative scarring grading system for each patient to determine the degree of improvement \[[@CR4]\].

### Clinical Assessment {#Sec10}

Standardized high-resolution digital photographs obtained using identical camera settings (Samsung, Seoul, South Korea) were obtained before the start of treatment and after the end of treatment.

### Clinical Improvement {#Sec11}

Two nontreating blinded physicians assessed the grade of improvement of skin smoothness by comparing photographs on a four-point scale as grade 4 (\> 75%) = excellent, grade 3 (51--75%) = marked, grade 2 (26--50%) = moderate, and grade 1 (0--25%) = minimal improvement.

### Clinical Satisfaction {#Sec12}

Patient satisfaction was recorded on a four-point scale as grade 4 (highly satisfied), grade 3 (satisfied), grade 2 (neutral), and grade 1 (dissatisfied).

### Assessment of Complications {#Sec13}

Follow-up for all patients was carried out after 1 week of each session for early complications. The degree of facial erythema was evaluated according to the Clinician Erythema Assessment (CEA) scale, graded as clear, almost clear, mild, and moderate.

Statistical Analysis {#Sec14}
--------------------

Data were verified, coded by the researcher, and analyzed using IBM-SPSS version 21 (©IBM-SPSS Inc., Armonk, NY, USA, 2012). Descriptive statistics (means, standard deviations, and percentages) were calculated. The chi-square test was used to test the significance of differences in the distribution of frequencies among different groups. For continuous variables, the analysis of variance (ANOVA) test was applied to test the mean differences of the data that followed a normal distribution, and the post hoc test was calculated using Bonferroni corrections. *P* values equal to or less than 0.05 are considered significant.

Compliance with Ethics Guidelines {#Sec15}
---------------------------------

Approval for this study was obtained from the institutional review board (IRB) of the Faculty of Medicine-South Valley University prior to study execution. The trial was registered on the clinical trial registration website (<https://clinicaltrials.gov/>, NCT03933033). The study was performed in accordance with the Declaration of Helsinki of 1964 and its later amendments. In addition, all participants were asked to sign a written consent form prior to participation. The informed consent was clear and indicated the purpose, process, benefits, and risks of the study, as well as their freedom to participate or withdraw at any time without any obligation. Furthermore, participant confidentiality and anonymity were ensured by assigning each participant a code number for the purpose of analysis only. The study was not based on any incentives or rewards for the participants.

Results {#Sec16}
=======

This trial included 75 patients with atrophic acne scars. Participant age ranged from 18 to 38 years with a mean of 26.7 ± 5.1 years. Twenty-seven patients were male (36%), and 48 patients were female (64%). The mean duration of their postacne scars was 4.6 ± 1.9 (range 1--8 years). There were no statistically significant differences in basic characteristics between the two study groups (Table [1](#Tab1){ref-type="table"}). Moreover, there was no significant difference between the study groups regarding scar duration, skin type, or scar type (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of the studied groupsPRP (*n* = 25)Er-YAG laser (*n* = 25)Both (*n* = 25)Age (years)26.68 ± 5.125.68 ± 5.326.60 ± 5.4Sex Male8 (32%)10 (40%)9 (36%) Female17 (68%)15 (60%)16 (64%)Occupation Working10 (40%)8 (32%)11 (44%) Not working15 (60%)17 (68%)14 (56%)Marital status Single10 (40%)11 (44%)10 (40%) Married13 (52%)13 (52%)13 (52%) Divorced2 (8%)1 (4%)2 (8%)Smoking4 (16%)5 (20%)4 (16%)Previous treatment Topical5 (20%)6 (24%)5 (20%) Isotretinoin0 (0%)0 (0%)0 (0%) Intervention6 (24%)4 (16%)6 (24%)Duration of scar (years)4.72 ± 1.74.56 ± 1.94.76 ± 1.6*P* value\*\**P*1 = 0.747*P*2 = 0.687*P*3 = 0.936Skin type III8 (32%)7 (28%)9 (36%) IV17 (68%)18 (72%)16 (64%)Scar type Boxcar9 (36%)10 (40%)10 (40%) Icepick10 (40%)7 (28%)9 (36%) Rolling6 (24%)8 (32%)6 (24%)\*\* Non significant difference

Likewise, the difference between the three groups in pretreatment acne scar grade was not statistically significant (*P* = 0.831). On the other hand, the three treated groups showed significant improvement in acne scar grading with a significant decrease in the severity of acne scars. Comparing the groups, patients treated with both Er-YAG laser and PRP showed a significant improvement compared with those treated with Er-YAG laser or PRP alone (*P* = 0.007 and *P* \< 0.001, respectively). Also, patients treated with Er-YAG laser showed more marked improvement than those treated with PRP (*P* \< 0.001) (Table [2](#Tab2){ref-type="table"}).Table 2Acne scar grading according to Goodman and BaronPRP (*n* = 25)Er-YAG laser (*n* = 25)Both (*n* = 25)*P* valuePretreatment0.831^a^ Macular0 (0%)0 (0%)0 (0%) Mild4 (16%)5 (20%)3 (12%) Moderate13 (52%)14 (56%)14 (56%) Severe8 (32%)6 (24%)8 (32%)Posttreatment0.004^**a**^\* Macular2 (8%)5 (20%)3 (12%) Mild7 (28%)11 (44%)17 (68%) Moderate11 (44%)7 (28%)5 (20%) Severe5 (20%)2 (8%)0 (0%)*P* value^a^*P*1 = 0.001*P*2 = 0.007*P*3 \< 0.001\* Significant^a^Chi-square test was used to compare the proportion difference between groups*P*1 = PRP versus laser, *P*2 = laser versus both, *P*3 = PRP versus both

Regarding clinical improvement, in group A, the improvement was minimal in 12 patients (48%), moderate in 9 patients (36%), marked in 3 patients (12%), and excellent in 1 patient (4%). Likewise, in group B, it was excellent in 1 patient (4%), marked in 12 patients (48%), moderate in 9 patients (36%), and minimal in 3 patients (12%). In group C, the improvement was excellent in 8 patients (32%), marked in 11 patients (44%), moderate in 5 patients (20%), and minimal in 1 patient (4%) The overall improvement was significantly greater in group C compared with group A or group B (*P* \< 0.001). Also, group B showed significantly greater clinical improvement than group A (*P* \< 0.012) (Table [3](#Tab3){ref-type="table"}) (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}).Table 3Treatment efficacy among the studied cohortPRP (*n* = 25)Er-YAG laser (*n* = 25)Both (*n* = 25)*P* valueClinical improvement Minimal12 (48%)3 (12%)1 (4%) Moderate9 (36%)9 (36%)5 (20%)\< 0.001^a^ Marked3 (12%)12 (48%)11 (44%) Excellent1 (4%)1 (4%)8 (32%)*P* value^a^*P*1 = 0.012*P*2 \< 0.001*P*3 \< 0.001Patient satisfaction Dissatisfied9 (36%)3 (12%)2 (8%) Neutral9 (36%)7 (28%)5 (20%)\< 0.001^a^ Satisfied6 (24%)12 (48%)11 (44%) Highly satisfied1 (4%)3 (12%)7 (28%)*P* value^a^*P*1 = 0.009*P*2 = 0.005*P*3 \< 0.001^a^Chi-square test was used to compare the proportion difference between groups*P*1 = PRP versus laser, *P*2 = laser versus both, *P*3 = PRP versus both. *P* \< 0.05 is significantFig. 1A 27-year-old female patient treated with combined Er-YAG 2940 nm laser and PRP sessions: **a** pretreatment, **b** posttreatmentFig. 2A 25-year-old female patient treated with PRP sessions: **a** pretreatment, **b** posttreatmentFig. 3A 24-year-old female patient treated with Er-YAG 2940 nm laser sessions only: **a** pretreatment, **b** posttreatment

Regarding patient satisfaction, in group A, about one-third of patients were either dissatisfied or neutral, a quarter of them were satisfied, while only one patient was highly satisfied. Meanwhile, in group B, 3 patients (12%) were highly satisfied, 12 (48%) were satisfied, 7 (28%) were neutral, and 3 (12%) were dissatisfied. Patients in group C were distributed as follows: 7 (28%) were highly satisfied, 11 (44%) were satisfied, 5 (20%) were neutral, and 2 (8%) were dissatisfied. In pairwise comparisons, patients in group C were more satisfied with their results than those in group A or B (*P* \< 0.001 and *P* = 0.005, respectively). Likewise, patients treated with Er-YAG laser were markedly more satisfied than those treated with PRP (*P* = 0.009) (Table [3](#Tab3){ref-type="table"}).

There were no statistically significant differences between the two study groups regarding any of the posttreatment complications (Table [4](#Tab4){ref-type="table"}).Table 4Complications of treatment modalities in studied groupsPRP (*n* = 25)Er-YAG laser (*n* = 25)Both (*n* = 25)*P* valuePosttreatment facial erythema0.323\* Clear9 (36%)10 (40%)8 (32%) Almost clear13 (52%)15 (60%)15 (60%) Mild3 (12%)0 (0%)2 (8%)Posttreatment PIH5 (20%)2 (8%)4 (16%)0.451\*Posttreatment acne-form eruption2 (12%)1 (4%)1 (4%)0.260\*\* Non significant

Discussion {#Sec17}
==========

Although there is no standard protocol for treatment of acne scars, many therapeutic interventions have been used, with variable clinical success and complications, including dermabrasion, microdermabrasion, microneedling, PRP, and ablative and nonablative fractional lasers \[[@CR14]\].

In the current work, the efficacy and safety of PRP, factional Er-YAG laser, and their combination for treatment of atrophic acne scars were compared. The results reveal marked efficacy of PRP in treating acne scars with an improvement in scar grade, clinical appearance, and patient satisfaction compared with their baseline measurements. These results coincide with previous studies that compared the efficacy of PRP, trichloroacetic acid, and microneedling for acne scars, which found significant efficacy of PRP with nonsignificant difference from the other lines \[[@CR15]--[@CR17]\]. In their work, Ibrahim et al. found that PRP was more effective than microneedling while combined treatment was more effective than either line alone \[[@CR16]\]. This can be explained by the fact that platelets contain alpha-granules and secrete several growth factors, such as transforming growth factor-beta, platelet-derived growth factor, vascular endothelial growth factor, and others \[[@CR17]\]. These growth factors and other proteins, such as adhesion molecules and chemokines, interact with the local environment to promote cell differentiation, proliferation, and regeneration and enhance proliferation of human adipose-derived stem cells, human-derived fibroblasts, and type 1 collagen \[[@CR18]\].

Moreover, patients treated with fractional Er-YAG laser showed a significant improvement in their acne scar grade, clinical appearance, and satisfaction as compared with their baseline, and also their improvement was significantly better than those treated with PRP alone, indicating a higher efficacy of fractional Er-YAG laser than PRP. These findings could be due to the fact that fractional Er-YAG laser provides less ablation and coagulation depth than fractional CO~2~ laser, yielding comparable efficacy with lower downtime and less side effects \[[@CR19]\]. Furthermore, the Er-YAG laser wavelength is 2940 nm, corresponding to the peak absorption coefficient of water, and is absorbed 12 times or more by cutaneous water-containing tissue than the 10,600 nm wavelength of the CO~2~ laser \[[@CR20]\].

The efficacy and safety of fractional Er-YAG laser in treatment of atrophic acne scars were investigated by Kirmal et al., who found it to be a highly effective and safe treatment modality for atrophic acne scars \[[@CR21]\]. In their pilot study, Firooz et al. reported that fractional Er-YAG laser was an effective and minimally invasive method for treatment of atrophic acne scars \[[@CR22]\]. The effect of Er-YAG laser was found to be greater in early scars than in those with long duration \[[@CR23]\]. It has been postulated that the coagulation mode of the fractional Er-YAG laser delivers energy more precisely without excessive thermal injury to adjacent tissue, which allows faster healing and an easy, effective, and safe method for acne scar treatment \[[@CR24]\].

In the present trial, patients who were treated with combined PRP and fractional Er-YAG laser showed significant improvement in their acne scar grade, clinical evaluation, and satisfaction compared with their baseline, and also when compared with those treated with either modality alone.

Although many data have been published on combined treatments for acne scars, few works on this combination (PRP and fractional Er-YAG laser) have been published. In their study, Zhu et al. found that PRP combined with erbium fractional laser therapy was a safe and effective approach for treating acne scars, with less side effects \[[@CR25]\]. The combination of PRP and fractional CO~2~ laser was found to be a more effective treatment modality for acne scars compared with PRP or CO~2~ laser alone \[[@CR26]\]. These better results (improvement of acne scars and fewer side effects) can be attributed to the synergistic effect when using both modalities simultaneously. Indeed, PRP enhances proliferation of human adipose-derived stem cells, human-derived fibroblasts, and type 1 collagen, which accelerates healing of laser-induced lesions \[[@CR25]\]. On the other hand, poor efficacy of fractional ablative laser in treating acne scars has been reported \[[@CR27], [@CR28]\].

Notwithstanding, no significant difference was detected between the groups regarding complications or side effects. These results are consistent with those of Gawdat et al., who did not report PIH after treatment with PRP, whereas it was reported in 13.3% of patients who received fractional CO~2~ laser alone; they concluded that the combination of topical PRP and fractional CO~2~ laser is an effective and safe modality for treatment of atrophic acne scars with shorter downtime than fractional CO~2~ laser alone and better tolerability than fractional CO~2~ laser combined with PRP \[[@CR29]\]. This may be because the faster repair of the basement membrane might reduce pigmentary incontinence, resulting in less pigmentation after laser. Another explanation might be that TGF-b, which is released by PRP, is also known to decrease melanogenesis. We believe that this action gives the combined protocol an advantage.

Limitations {#Sec18}
-----------

The main limitation of the present trial is the short follow-up period.

Conclusions {#Sec19}
===========

Both PRP and fractional Er-YAG laser were found to be effective and safe for treatment of acne scars, but their combination was found to be superior to either line of treatment alone, with better results and higher tolerability and patient satisfaction.
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